99mTc-HMPAO distribution at SPECT is associated with succinate-cytochrome c reductase (SCR) activity in subjects with psychiatric disorders

Nuclear Medicine and Biology

Volumn 31, Issue 2, 2004, Pages 277-282

  Gardner, Ann ^a   Pagani, Marco ^a,b   Beier, Henning ^c   Jacobsson, Hans ^a   Larsson, Stig A ^a   Hällström, Tore ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF COGNITIVE SCIENCES AND TECHNOLOGIES   (Italy)

^c University Teaching Hospital Ryhov   (Sweden)

Author keywords

99mTc d; l hexamethylpropyleneamine oxime; Major depressive disorder; Mitochondria; Schizophrenia; SCR; Succinate cytochrome c oxidoreductase

Indexed keywords

HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; DIAGNOSTIC AGENT;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTRON; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MENTAL DISEASE; MUSCLE BIOPSY; OXIDATION REDUCTION REACTION; SENSORY CORTEX; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; BRAIN; CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; METHODOLOGY; MUSCLE MITOCHONDRION; SCINTISCANNING; SKELETAL MUSCLE; STATISTICS; TISSUE DISTRIBUTION; VALIDATION STUDY;

ADULT; BRAIN; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; RADIOPHARMACEUTICALS; STATISTICS; SUCCINATE CYTOCHROME C OXIDOREDUCTASE; TECHNETIUM TC 99M EXAMETAZIME; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 1542345721     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00130-6     Document Type: Article

References (39)

1. Sabri O., Erkwoh R., Schreckenberger M., Owega A., Sass H., Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 349:1997;1735-1739.
2. Conca A., Fritzsche H., Peschina W., König P., Swoboda E., Wiederin H., Haas C. Preliminary findings of simultaneous 18F-FDG and 99mTc-HMPAO SPECT in patients with depressive disorders at rest differential correlates with ratings of anxiety. Psychiat Res. 98:2000;43-54.
3. Gardner A., Pagani M., Wibom R., Nennesmo I., Jacobsson H., Hällström T. Alterations of rCBF and mitochondrial dysfunction in major depressive disorder a case report. Acta Psychiatr Scand. 107:2003;233-239.
4. Ledberg A. Measuring brain functions: statistical tests for neuroimaging data [thesis]. Department of Neuroscience. 2001;Karolinska Institutet, Stockholm.
5. Neirinckx R.D., Canning L.R., Piper I.M., Nowotnik D.P., Pickett R.D., Holmes R.A., Volkert W.A., Forster A.M., Weisner P.S., Marriott J.A., Chaplin S.B. Technetium 99m d,l-HM-PAO a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med. 28:1987;191-202.
6. Babich J.W. Technetium-99m-HMPAO retention, and the role of glutathione the debate continues. J Nucl Med. 32:1991;1681-1683.
7. Ballinger J.R., Reid R.H., Gulenchyn K.Y. Technetium-99m HM-PAO stereoisomers differences in interaction with glutathione. J Nucl Med. 29:1988;1998-2000.
8. Neirinckx R.D., Burke J.F., Harrison R.C., Forster A.M., Andersen A.R., Lassen N.A. The retention mechanism of technetium-99m-HM-PAO intracellular reaction with glutathione. J Cereb Blood Flow Metab. 8:1988;S4-12.
9. Sasaki T., Toyama H., Oda K., Ogihara-Umeda I., Nishigori H., Senda M. Assessment of antioxidative ability in brain technetium-99m-meso-HMPAO as an imaging agent for glutathione localization. J Nucl Med. 37:1996;1698-1701.
10. Sasaki T., Fujibayashi Y., Senda M. Distribution of glutathione and technetium-99m-meso-HMPAO in normal and diethyl maleate-treated mouse brain mitochondria. J Nucl Med. 39:1998;2178-2183.
11. Fujibayashi Y., Taniuchi H., Waki A., Yokoyama A., Ishii Y., Yonekura Y. Intracellular metabolism of 99mTc-d,l-HMPAO in vitro a basic approach for understanding the hyperfixation mechanism in damaged brain. Nucl Med Biol. 25:1998;375-378.
12. Jacquier-Sarlin M.R., Polla B.S., Slosman D.O. Oxido-reductive state the major determinant for cellular retention of technetium-99m-HMPAO. J Nucl Med. 37:1996;1413-1416.
13. Watanabe Y., Hashikawa K., Moriwaki H., Oku N., Seike Y., Kodaka R., Ono J., Uehara T., Kusuoka H., Nishimura T. SPECT findings in mitochondrial encephalomyopathy. J Nucl Med. 39:1998;961-964.
14. Peng N.J., Liu R.S., Li J.Y., Tsay D.G., Kong K.W., Kwok C.G., Strauss H.W. Increased cerebral blood flow in MELAS shown by Tc-99m HMPAO brain SPECT. Neuroradiology. 42:2000;26-29.
15. Rustin P., Rotig A. Inborn errors of complex II - unusual human mitochondrial diseases. Biochim Biophys Acta. 1553:2002;117-122.
16. Mourmans J., Wendel U., Bentlage H.A., Trijbels J.M., Smeitink J.A., de Coo I.F., Gabreëls F.J., Sengers R.C., Ruitenbeek W. Clinical heterogeneity in respiratory chain complex III deficiency in childhood. J Neurol Sci. 149:1997;111-117.
17. Battino M., Bertoli E., Formiggini G., Sassi S., Gorini A., Villa R.F., Lenaz G. Structural and functional aspects of the respiratory chain of synaptic and nonsynaptic mitochondria derived from selected brain regions. J Bioenerg Biomembr. 23:1991;345-363.
18. Friede R.L. A comparative study of cytoarchitectonics and chemoarchitectonics of the cerebral cortex of the guinea pig. Z Zellforsch Mikrosk Anat. 52:1960;482-493.
19. Friede R.L. Topographic brain chemistry. 1966;Academic Press, New York. 16-131, 492-500.
20. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 55:1998;694-700.
21. Engel W.K., Meltzer H. Histochemical abnormalities of skeletal muscle in patients with acute psychoses. Science. 168:1970;273-276.
22. Meltzer H.Y. Skeletal muscle abnormalities in patients with affective disorders. J Psychiat Res. 10:1973;43-57.
23. Borg J., Edström L., Bjerkenstedt L., Wiesel F.-A., Farde L., Hagenfeldt L. Muscle biopsy findings, conduction velocity and refractory period of single motor nerve fibres in schizophrenia. J Neurol Neurosurg Psychiatry. 50:1987;1655-1664.
24. Gardner A., Johansson A., Wibom R., Nennesmo I., von Döbeln U., Hagenfeldt L., Hällström T. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord. 76:2003;55-68.
25. Gardner A., Wibom R., Nennesmo I., von Döbeln U., Beier H., Hagenfeldt L., Hällström T. Mitochondrial function in neuroleptic-free and medicated schizophrenia [abstract]. Mitochondrion. 1:2002;520.
26. Greitz T., Bohm C., Holte S., Eriksson L. A computerized brain atlas construction, anatomical content, and some applications. J Comp Assist Tomogr. 15:1991;26-38.
27. Thurfjell L., Bohm C., Bengtsson E. CBA - an atlas-based software tool used to facilitate the interpretation of neuroimaging data. Comput Methods Programs Biomed. 4:1995;51-71.
28. Jonsson C., Pagani M., Johansson L., Thurfjell L., Jacobsson H., Larsson S.A. Reproducibility and repeatability of normal resting state 99Tcm-HMPAO rCBF SPET using brain atlas matching. Nucl Med Commun. 21:2000;9-18.
29. Pagani M., Salmaso D., Jonsson C., Hatherly R., Jacobsson H., Larsson S.A., Wägner A. Regional cerebral blood flow as assessed by principal component analysis and (99m)Tc-HMPAO SPET in healthy subjects at rest normal distribution and effect of age and gender. Eur J Nucl Med Mol Imaging. 29:2002;67-75.
30. Gardner A., Pagani M., Jacobsson H., Lindberg G., Larsson S.A., Wägner A., Hällström T. Differences in resting state rCBF assessed with 99mTc-HMPAO SPECT and brain atlas matching between depressed patients with and without tinnitus. Nucl Med Commun. 23:2002;429-439.
31. Birch-Machin M.A., Briggs H.L., Saborido A.A., Bindoff L.A., Turnbull D.M. An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria. Biochem Med Metab Biol. 51:1994;35-42.
32. Cooperstein S.J., Lazarow A., Kurfess N.J. A microspectrophotometric method for the determination of succinic dehydrogenase. J Biol Chem. 186:1950;129-139.
33. Alp P.R., Newsholme E.A., Zammit V.A. Activities of citrate synthase and NAD+-linked and NADP+-linked isocitrate dehydrogenase in muscle from vertebrates and invertebrates. Biochem J. 154:1976;689-700.
34. Gille L., Nohl H. The ubiquinol/bc1 redox couple regulates mitochondrial oxygen radical formation. Arch Biochem Biophys. 388:2001;34-38.
35. Lenaz G. The mitochondrial production of reactive oxygen species mechanisms and implications in human pathology. IUBMB Life. 52:2001;159-164.
36. Farkas-Bargeton E., Diebler M.F., Rosenberg B., Wehrle R. Histochemical changes of the developing human cerebral neocortex. Studies on two enzymes of energy metabolism in three cortical areas. Neuropediatrics. 15:1984;82-91.
37. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
38. Blass J.P. Mitochondria, neurodegenerative diseases, and selective neuronal vulnerability. Ann NY Acad Sci. 893:1999;434-439.
39. Whatley S.A., Curti D., Marchbanks R.M. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 21:1996;995-1004.